Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Astellas) 7465-CL-0301An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)Hotte, Dr Sebastien Open to recruitmentNCT03474107
(AstraZeneca) D933IC00003 / BAYOUA Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineligible Patients With Unresectable Stage IV Urothelial CancerMukherjee, Dr SomOpen to recruitmentNCT03459846
(Bayer) BAY 1163877 / 17403 / FORT-1A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of
rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive
locally advanced or metastatic urothelial carcinoma who have received prior platinum containing
chemotherapy
Hotte, Dr Sebastien Open to recruitmentNCT03410693
(BMS) CA018005 / FRACTION-RCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Participants with Advanced Renal Cell Carcinoma
Hotte, Dr Sebastien Open to recruitmentNCT02996110
(BMS) CA2099KD / CheckMate 9KDA Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or
Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:
CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)
Hotte, Dr Sebastien Open to recruitmentNCT03338790
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpen to recruitmentNCT03385655 (Master)
(CCTG) IND.234 / PC-BETS - Sub-Study IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT02905318
(CCTG) IND.234A/PC-BETS Sub-Study AA Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655 (A)
(CCTG) IND.234B/PC-BETS Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(B)
(CCTG) IND.234C/PC-BETS Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(C)
(Clovis) CO-338-052 / TRITON2A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination DeficiencyHotte, Dr Sebastien Open to recruitmentNCT02952534
(EISAI) E7080-G000-218 / HOPEA Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted TreatmentHotte, Dr Sebastien Open to recruitmentNCT03173560
(JCC) Prostate HBINon-Targeted Low Dose Radiotherapy For Recurrent Prostate CancerDayes, Dr IanOpen to recruitmentNCT03196778
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosOpen to recruitmentNCT02685397
(Merck) MK-3475-564 / KEYNOTE 564A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)Lalani, Dr Aly-KhanOpen to recruitmentNCT03142334
(PHRI) RADICAL PC2A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer PatientsLeong, Dr DarrylOpen to recruitmentNCT03127631
(Roche) CO39303A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER Mukherjee, Dr SomOpen to recruitmentNCT03072238
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomOpen to recruitmentNCT02462239
OCOG-2016-MISTERAssessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer Hotte, Dr Sebastien Open to recruitmentNCT02813226
(UHN) TOPCOPTOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study)Hotte, Dr Sebastien Suspended/On holdNCT02512185
Download PDF